0000000000907854
AUTHOR
Francesca Costantini
showing 28 related works from this author
Occurrence of S100A7 in a large sample-set of breast cancer tissues
2010
Clinicopathological correlations of MMP-2 and MMP-9 in breast cancer
2009
Differential proteomics of thyroid carcinoma cell lines
2011
Herceptin Resistance and Malignant Potential of Cancer Cells.
2009
Proteomic analysis of Herceptin-resistance breast cancer cells
2009
Differential occurrence of S100A7 in breast cancer tissues: A proteomic-based investigation
2012
Purpose The present study reports for the first time a large-scale proteomic screening of the occurrence, subcellular localization and relative quantification of the S100A7 protein among a group of 100 patients, clinically grouped for the diagnosis of infiltrating ductal carcinoma (IDC). Experimental design To this purpose, the methods of differential proteomics, Western blotting, and immunohistochemistry were used. Results The identity of two isoforms of the protein was assessed by mass spectrometry and immunologically confirmed. Moreover, we proved by immunocytochemical applications the exclusive localization of the protein within the neoplastic cells. The correlation of S100A7 expression…
Dibutyltin(IV) and Tributyltin(IV) Derivatives of meso-Tetra(4 sulfonatophenyl)porphine Inhibit the Growth and the Migration of Human Melanoma Cells.
2019
Melanoma is the most aggressive and deadly form of skin cancer, which is largely due to its propensity to metastasize. Therefore, with the aim to inhibit the growth and the metastatic dissemination of melanoma cells and to provide a novel treatment option, we studied the effects of the melanoma treatment with two organotin(IV) complexes of the meso-tetra(4-sulfonato-phenyl)porphine, namely (Bu2Sn)2TPPS and (Bu3Sn)4TPPS. In particular, we showed that nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS are sufficient to inhibit melanoma cell growth, to increase the expression of the full-length poly (ADP-ribose) polymerase (PARP-1), to induce the cell cycle arrest respectively at G2/M a…
Multiple changes induced by fibroblasts on breast cancer cells.
2010
It is now widely recognised that the cross-talk between cancer and stromal cells may play a crucial role in cancer progression. However little is known about the complex underlying molecular mechanisms that occur within the tumor microenvironment. Fibroblasts are the major stromal cells with multiple roles, especially towards both the extracellular matrix and the neighbouring cell population, including neoplastic cells. Consequently, proteomic analyses would provide a wider resource for a better understanding of the potential modulating effects exerted by fibroblasts on cancer cells. In this report we describe the effects of fibroblast stimulation on the breast cancer cell line (8701-BC) pr…
S100S PROTEIN EXPRESSION IN A LARGE SAMPLE-SET OF BREAST CANCER TISSUES
2010
S100 proteins are low molecular weight proteins ranging in size from 9 to 13 kDa. They form homo- and heterodimers and even oligomers and are expressed in tissue and cell-specific manner [1]. It is well documented, infact, that S100 proteins have a broad range of intracellular and extracellular functions. Intracellular functions include regulation of protein phosphorylation, enzyme activity, calcium homeostasis, regulation of cytoskeletal components and regulation of transcriptional factors, so they are involved in several biological processes including cell cycle regulation, cell growth, cell differentiation, and motility [2]. Extracellularly they act in a cytokine like manner through the …
Evaluation of cellular response of breast cancer cells grown on distinctive collagen substrates
2008
LARGE-SCALE COMPARATIVE PROTEOMICS OF BREAST CANCER SURGICAL TISSUES
2009
Comparative proteomics of breast cancer surgical tissues
2009
Gene ontology-based annotation and comparative analysis of proteins extracted from proteomics of 100 breast cancer patients.
2009
Background: Current clinical parameters for breast cancer diagnosis and therapy are: tumour size, axillary lymph node status, histological grading and presence or absence of metastases. Prognostic/predictive properties, such as oestrogen and progesterone receptor status, and human epidermal growth factor receptor (HER-2/neu) status are currently used for therapeutic decision. Conversely, it is now emerging that the number of genetic mutations and epigenetic deregulations in cancer is far more higher than previously thought. Therefore, proteomic screening for differential protein expression in subsets of tumor samples is an essential tool for generating data bases and biomarker discovery. Th…
Proteomic modulation induced in fibroblasts by breast cancer cells (8701‐BC)paracrine factors.
2009
Large-scale proteomic identification of S100 proteins in breast cancer tissues
2010
Abstract Background Attempts to reduce morbidity and mortality in breast cancer is based on efforts to identify novel biomarkers to support prognosis and therapeutic choices. The present study has focussed on S100 proteins as a potentially promising group of markers in cancer development and progression. One reason of interest in this family of proteins is because the majority of the S100 genes are clustered on a region of human chromosome 1q21 that is prone to genomic rearrangements. Moreover, there is increasing evidence that S100 proteins are often up-regulated in many cancers, including breast, and this is frequently associated with tumour progression. Methods Samples of breast cancer t…
CIRCULATING AND TISSUE FORMS OF MMP2 AND MMP9 IN BREAST CANCER PROGRESSION
2010
Tumor progression and metastasis represent the leading causes of cancer related death. One of the major features that may contribute to neoplastic cell dissemination is the progressive and local degradation of the extracellular matrix (ECM) surrounding the primary tumour. Degradation of the ECM requires the coordinated action of a number of enzymes produced locally by neoplastic cells and/or stromal cells. Five categories of proteinases have been implicated in the invasive process: serine, cysteine, aspartic, threonine proteinases and matrix metalloproteinases (MMPs), also known as matrixins, which play a key role as terminal effectors of the proteolytic cascade. At present 23 members of th…
IDENTIFICATION OF PROTEOMIC CLUSTERS RELATED TO THE BREAST CANCER PROGRESSION
2011
DIFFERENTIAL PROTEOMIC ANALYSIS OF THYROID CARCINOMA CELL LlNES
2011
Herceptin-resistance in breast cancer cells: a proteomic study.
2009
HER-2 is a cell membrane protein that belongs to the ErbB family of receptor tyrosine kinases (HER-1, HER-2, HER-3, HER-4). The over-expression of HER-2, which results in the 25-30% of breast cancer patients, is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness and makes HER-2 an excellent therapeutic target. In the last years new therapeutic strategies have been improved in order to better deal tumor diseases an to minimize collateral effects due to classic chemotherapy in patients. In this way, a new approach was the somministration of humanized antibodies directed against tumor-associated molecular targets. Among these ones Herceptin, an anti-neo…
Proteomic detection of S100 proteins in breastcancer tissues
2010
Multiple effects induced by herceptin® on 8701-BC breast cancer cells
2008
Herceptin, an anti-neoplastic humanized monoclonal antibody (Herceptin®, Roche, CH), has been shown to be active against breast cancer cells over-expressing HER-2 receptor. HER-2 is a cell membrane protein that belongs to the epidermal growth factor receptors family and that results over-expressed in the 25-30% of breast cancer patients. The over-expression of HER-2 is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness. On these bases, we aimed to analyze the effects caused by Herceptin treatment on 8701-BC breast cancer cells (Minafra et al., 1989). Firstly we evaluated the effects of Herceptin on the growth rate of 8701-BC cells. To this purpose, p…
Herceptin-resistance in breast cancer cells: a proteomic approach
2009
Large-scale comparative proteomics of breast surgical tissues
2009
S-100 calcium binding proteins as potential markers for breast cancer metastasis.
2009
The S-100 family of calcium-binding proteins includes about 20 members of low molecular weight characterized by two consecutive EF hands domains. They make interactions with cellular target proteins in a calcium-dependent manner; therefore they are thought to regulate a variety of physiological functions, such as cell proliferation, signal transduction, cell adhesion, motility as well as cancer metastasis.
Permissive and restrictive influences from breast cancer stroma
2010
The turn-over of extracellular matrix is a physiological process, that in normal conditions and in wound healing respond to spatial and temporal regulatory mechanisms, involving several cell-matrix interaction pathways. Profound changes occur both at cellular and extracellular level, during the progression of various forms of invasive carcinomas. Collagen alterations and cellular effects. The ultrastructural and biochemical analyses of the collagenous stroma of invasive ductal breast carcinoma have demonstrated the occurrence of extensive fragmentation of pre-existing collagen fibrils and new deposition of thinner fibrils formed mostly by 1(I)3 homotrimer collagen of type I [1-3], which app…